Paper Details

  1. Home
  2. Paper Details

Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.

Author: LebwohlMark G, SinghFiza

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Combination therapy with bexarotene and psoralen plus ultraviolet A (PUVA) may be considered for patients with treatment-resistant cutaneous T-cell lymphoma (CTCL) refractory to monotherapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mycosis fungoides, the most common form of cutaneous T-cell lymphoma, often presents as chronic eczematous or psoriasiform patches and plaques that can be resistant to a variety of single-agent treatment modalities, necessitating combination therapy. OBJECTIVE: To evaluate the efficacy ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15389192

データ提供：米国国立医学図書館（NLM）

Cutaneous T-Cell Lymphoma: A Journey of Treatment Resistance

This study takes us on a journey through the desert of cutaneous T-cell lymphoma (CTCL), a type of cancer that affects the skin. The researchers explore the effectiveness of a combination therapy using bexarotene and PUVA, a treatment that involves psoralen and ultraviolet A light. It's like searching for a hidden oasis in the desert, seeking a combination of resources to overcome the challenges of this complex condition.

A Multifaceted Approach to CTCL

This study highlights the importance of exploring multi-pronged approaches to treat resistant cancers, like discovering multiple water sources in a dry desert. It's about combining different therapies to maximize effectiveness and improve outcomes. The researchers report positive responses in patients who had previously failed multiple single-agent treatments, suggesting that the combined approach can be a valuable option for those struggling with resistant CTCL.

Navigating the Desert of Cancer

This study offers hope for patients with CTCL, showcasing the potential of combination therapy to overcome treatment resistance. It's like finding a way to overcome the challenges of a desert journey, utilizing a variety of resources to achieve success. By exploring new treatment options and combining different approaches, we can improve outcomes for those facing the challenges of cancer.

Dr. Camel's Conclusion

This research explores the effectiveness of combination therapy with bexarotene and PUVA in treating resistant cutaneous T-cell lymphoma, highlighting the importance of exploring multi-pronged approaches to manage this challenging condition.

Date :
  1. Date Completed 2005-04-11
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

15389192

DOI: Digital Object Identifier

S0190962204018705

Related Literature

Article Analysis
・Effects of bexarotene topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.